甲状腺疾病患者血清可溶性细胞间黏附分子-1测定的临床意义

Clinical value of soluble intercellular adhesion molecule -1 in patients with thyroid disease

目的 探讨单纯甲状腺肿、格雷夫斯病（GD）和桥本甲状腺炎（HT）患者血清可溶性细胞间黏附分子-1（sICAM-1）的含量及其临床意义.方法 用放射免疫分析法检测单纯性甲状腺肿大100例、GD 250例、HT 50例及健康人对照组100例血清sICAM-1含量,进行比较分析.结果 健康人sICAM-1含量（170.43±34.23）μg/L和单纯性甲肿（182.48±40.05）μg/L差异无统计学意义（t=1.104,P＞0.05）;GD和HT的sICAM-1含量分别为（279.93±86.69）μg/L,（250.36±81.56）μg/L,均高于对照组（t=2.310,2.210,均P＜0.05）;三种方法治疗后sICAM-1含量[（178.95±59.78）μg/L,（185.65±53.25）μg/L,（259.41±71.46）μg/L）]均明显低于治疗前[（316.53±66.13）μg/L,（277.79±64.30）μg/L,（285.71±72.14）μg/L]（t=2.312,2.278,2.328,均P＜0.05）;GD停药复发患者血清sICAM-1为（329.34±90.47）μg/L,明显高于抗甲状腺药物治疗后甲状腺功能恢复正常的GD患者（251.92±77.75）μg/L（t=2.412,P＜0.05）.结论 血清sICAM-1含量可作为自身免疫性甲状腺疾病诊断的一个参考指标,并在临床评价Graves病的疗效、停药和复发等方面具有重要意义.

Objective To explore the contents and clinical significance of soluble intracellular adhesion molecule-1 （ sICAM-1 ） in patients with single goitre,Graves＇and Hashimoto disease. Methods The contents of sICAM-1 in 100 cases of simple goiter group, Graves disease （GD） group 250 cases, Hashimot group 50 cases and 100 normal control were examined by sICAM-1 Radioimmunoassay（RIA） method,and the results were analyzed. Results There were no significant difference of sICAM-1 contents between （ 170.43 ± 34. 23 ） μg/L in normal control group and （ 182.48 ± 40.05） μg/L in simple goiter group（ t = 1. 104, P ＞ 0. 05 ）; The contents of slCAM-1 in GD group and HT group [（ 279.93 ± 86.69） μg/L、 （250.36 ± 81.56） μg/L] were higher than the control group（ t = 2.310,2. 210, all P ＜0. 05） ;The sICAM-1 contents in 3 species.methods after treatment [（ 178.95 ±59.78） μg/L, （ 185.65 ±53.25）μg/L, （259.41 ± 71.46） μg/L）] were significantly lower than before treatment [（316.53 ± 66.13） μg/L, （277.79±64.30）μg/L,（285.71 ±72.14）μg/L]（t=2.312,2.278,2.328,all P ＜0.05）;After the Graves＇patients were treated and their thyroid function were normal,their serum sICAM-1 levels（ 251.92 ± 77.75 ）μg/L were lower than that（ 329.34 ± 90.47 ） μg/L in relapse Graves＇group（ t= 2.412 ,P ＜ 0. 05）. Conclusion sICAM-1 RIA can be used as a parameter in diagnosing autoimmune thyroid diseases and in evaluating effects of therapy,stopping medicine or the relapse of Graves＇ disease.